超短程糖皮质激素后托珠单抗单药治疗巨细胞动脉炎:单臂开放标签概念验证研究
这项单中心单臂开放标签概念验证试验纳入18例新发巨细胞动脉炎患者,先接受3天甲泼尼龙500 mg静脉注射,后予托珠单抗单药治疗至52周。主要终点未达到(12例中3例缓解),但24周内14例(78%)缓解,52周时13例(72%)无复发,提示托珠单抗起效较慢但维持缓解持久,作为概念验证研究尚不能提出临床推荐。
要点
- 超短程激素后托珠单抗单药可使多数新发巨细胞动脉炎患者24周内缓解。
- 托珠单抗起效较慢,主要终点未达到,研究对主要终点无效。
- 52周时72%患者无复发,但2例因不良事件停药,1例发生前部缺血性视神经病变。
核心结论
- 超短程糖皮质激素脉冲后托珠单抗单药在新发巨细胞动脉炎中显示缓慢诱导缓解和持久维持缓解的效果。
- 作为概念验证研究,数据不足以提出临床推荐。
研究设计与样本
- 研究者发起的单臂、单中心、开放标签、概念验证试验,采用Simon两阶段设计,在瑞士伯尔尼大学医院进行。
- 纳入年龄>50岁、新诊断巨细胞动脉炎(筛查前4周内)且符合美国风湿病学会标准或伴大血管炎相关风湿性多肌痛的患者。
- 共纳入18例患者(12/18为女性,18/18为白人),中位年龄72岁(IQR 67-75)。
- 治疗方案:甲泼尼龙500 mg静脉注射连续3天,随后停用糖皮质激素,予托珠单抗8 mg/kg单次静脉输注,之后每周皮下注射162 mg至52周。
- 主要终点:31天内缓解且第24周无复发的患者比例;次要终点包括第24和52周完全无复发缓解比例及至首次缓解、首次复发、首次部分缓解的时间。
主要发现
- 中期分析时12例中3例(25%)缓解,无效假设未被拒绝,研究对主要终点无效。
- 18例中13例(72%,95%CI 47-90)至52周无复发。
- 18例中3例无应答,2例因不良事件停药(肝病1例、憩室炎1例),1例发生前部缺血性视神经病变。
关键数值与推荐
- 主要终点缓解定义为31天内缓解且第24周无复发,中期分析12例中3例(25%)达到。
- 52周无复发率72%(13/18,95%CI 47-90)。
临床怎么用
- 超短程激素后托珠单抗单药可能作为新发巨细胞动脉炎的候选方案,但起效较慢,需密切监测病情活动。
- 治疗期间需警惕不良事件,包括肝病、憩室炎和前部缺血性视神经病变。
- 因系概念验证研究,尚不能据此形成临床推荐,需等待进一步随机对照研究验证。
局限性
- 单臂、单中心、开放标签设计,样本量小(18例),无对照组。
- 主要终点未达到,研究对主要终点无效。
- 作者指出作为概念验证研究,数据不允许提出临床推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two randomised controlled trials showed a glucocorticoid-sparing effect of tocilizumab in patients with giant cell arteritis. In the GUSTO trial we aimed to evaluate the efficacy and safety of tocilizumab monotherapy after ultra-short-term glucocorticoid treatment in patients with new-onset giant cell arteritis. METHODS: This investigator-initiated, single-arm, single-centre, open-label, proof-of-concept trial with a Simon's two stage design was done at University Hospital Bern, Bern, Switzerland. We enrolled patients aged older than 50 years newly diagnosed with giant cell arteritis (within 4 weeks before the screening visit) satisfying the American College of Rheumatology criteria or with large vessel vasculitis-associated polymyalgia rheumatica. The participants received 500 mg methylprednisolone intravenously for 3 consecutive days. Thereafter, glucocorticoid treatment was discontinued and a single infusion of tocilizumab (8 mg/kg bodyweight) was administered intravenously, followed by weekly subcutaneous tocilizumab injections (162 mg) until week 52. The primary endpoint was the proportion of patients who had remission within 31 days and showed no relapse at week 24. The secondary endpoints were the proportion of patients with complete relapse-free remission of disease at weeks 24 and 52, and time to first remission, first relapse (after induction of remission), and first partial remission. This study is registered with ClinicalTrials.gov, NCT03745586. FINDINGS: From Nov 23, 2018, to Sept 22, 2019, 18 patients were enrolled (12 of 18 were female, 18 of 18 were White) with a median age of 72 (IQR 67-75) years. Overall, 15 of 18 patients had cranial symptoms, ten of 18 had polymyalgia rheumatica symptoms, and 13 of 18 showed a positive histopathology. At the interim analysis, three (25%) of 12 patients were in remission. The null hypothesis could not be rejected, and the study was futile with respect to the primary endpoint. However, 14 (78%) of 18 patients had remission within 24 weeks (mean time to first remission 11·1 weeks, 95% CI 8·3-13·9) and 13 of 18 showed no relapses up to 52 weeks (72%, 47-90). Mean time to first partial remission was 6·2 [3·7-8·7] weeks. Time to first relapse (after induction of remission) could not be estimated as there was no relapse after induction of remission. Overall, three of 18 patients did not respond to treatment and two of 18 discontinued the study due to an adverse event (hepatopathy [one] and diverticulitis [one]). Anterior ischaemic optic neuropathy occurred in one patient. INTERPRETATION: The data show a slow remission-inducing and a lasting remission-maintaining effect of tocilizumab after an ultra-short pulse of glucocorticoids in patients with newly diagnosed giant cell arteritis. As a proof-of-concept study, our data do not allow us to propose clinical recommendations. FUNDING: Bern University Hospital, University of Bern, and F Hoffmann-La Roche.
引用
- Christ L, Seitz L, Scholz G, et al. Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2021. PMID: 38287611. doi:10.1016/S2665-9913(21)00152-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。